Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma (Oncogene, (2022), 41, 21, (2973-2983), 10.1038/s41388-022-02305-x)

Patience Odeniyide; Marielle E. Yohe; Kai Pollard; Angelina V. Vaseva; Ana Calizo; Lindy Zhang; Fausto J. Rodriguez; John M. Gross; Amy N. Allen; Xiaolin Wan; Romel Somwar; Karisa C. Schreck; Linda Kessler; Jiawan Wang; Christine A. Pratilas

doi:10.1038/s41388-022-02342-6

Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma (Oncogene, (2022), 41, 21, (2973-2983), 10.1038/s41388-022-02305-x)

Patience Odeniyide, Marielle E. Yohe, Kai Pollard, Angelina V. Vaseva, Ana Calizo, Lindy Zhang, Fausto J. Rodriguez, John M. Gross, Amy N. Allen, Xiaolin Wan, Romel Somwar, Karisa C. Schreck, Linda Kessler, Jiawan Wang, Christine A. Pratilas

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Following the publication of this article a number of copy editing omissions were noted. These have now been corrected.

Original language	English (US)
Pages (from-to)	3037
Number of pages	1
Journal	Oncogene
Volume	41
Issue number	21
DOIs	https://doi.org/10.1038/s41388-022-02342-6
State	Published - May 20 2022

ASJC Scopus subject areas

Genetics
Molecular Biology
Cancer Research

Access to Document

10.1038/s41388-022-02342-6

Cite this

Odeniyide, P., Yohe, M. E., Pollard, K., Vaseva, A. V., Calizo, A., Zhang, L., Rodriguez, F. J., Gross, J. M., Allen, A. N., Wan, X., Somwar, R., Schreck, K. C., Kessler, L., Wang, J., & Pratilas, C. A. (2022). Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma (Oncogene, (2022), 41, 21, (2973-2983), 10.1038/s41388-022-02305-x). Oncogene, 41(21), 3037. https://doi.org/10.1038/s41388-022-02342-6

Odeniyide, P, Yohe, ME, Pollard, K, Vaseva, AV, Calizo, A, Zhang, L, Rodriguez, FJ, Gross, JM, Allen, AN, Wan, X, Somwar, R, Schreck, KC, Kessler, L, Wang, J & Pratilas, CA 2022, 'Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma (Oncogene, (2022), 41, 21, (2973-2983), 10.1038/s41388-022-02305-x)', Oncogene, vol. 41, no. 21, pp. 3037. https://doi.org/10.1038/s41388-022-02342-6

@article{96cf3f9f721649e99b4207c4d72880a2,

title = "Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma (Oncogene, (2022), 41, 21, (2973-2983), 10.1038/s41388-022-02305-x)",

abstract = "Following the publication of this article a number of copy editing omissions were noted. These have now been corrected.",

author = "Patience Odeniyide and Yohe, {Marielle E.} and Kai Pollard and Vaseva, {Angelina V.} and Ana Calizo and Lindy Zhang and Rodriguez, {Fausto J.} and Gross, {John M.} and Allen, {Amy N.} and Xiaolin Wan and Romel Somwar and Schreck, {Karisa C.} and Linda Kessler and Jiawan Wang and Pratilas, {Christine A.}",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = may,

day = "20",

doi = "10.1038/s41388-022-02342-6",

language = "English (US)",

volume = "41",

pages = "3037",

journal = "Oncogene",

issn = "0950-9232",

publisher = "Nature Publishing Group",

number = "21",

}

TY - JOUR

T1 - Correction

T2 - Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma (Oncogene, (2022), 41, 21, (2973-2983), 10.1038/s41388-022-02305-x)

AU - Odeniyide, Patience

AU - Yohe, Marielle E.

AU - Pollard, Kai

AU - Vaseva, Angelina V.

AU - Calizo, Ana

AU - Zhang, Lindy

AU - Rodriguez, Fausto J.

AU - Gross, John M.

AU - Allen, Amy N.

AU - Wan, Xiaolin

AU - Somwar, Romel

AU - Schreck, Karisa C.

AU - Kessler, Linda

AU - Wang, Jiawan

AU - Pratilas, Christine A.

PY - 2022/5/20

Y1 - 2022/5/20

N2 - Following the publication of this article a number of copy editing omissions were noted. These have now been corrected.

AB - Following the publication of this article a number of copy editing omissions were noted. These have now been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85129754146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85129754146&partnerID=8YFLogxK

U2 - 10.1038/s41388-022-02342-6

DO - 10.1038/s41388-022-02342-6

M3 - Comment/debate

C2 - 35534540

AN - SCOPUS:85129754146

SN - 0950-9232

VL - 41

SP - 3037

JO - Oncogene

JF - Oncogene

IS - 21

ER -

Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma (Oncogene, (2022), 41, 21, (2973-2983), 10.1038/s41388-022-02305-x)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this